AOD9604 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-12-17. Anything still debated is marked as such rather than presented as settled.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
The history of pathology can be traced to the earliest application of the scientific method to the field of medicine, a development which occurred in the Middle East during the Islamic Golden Age and in Western Europe during the Italian Renaissance. Early systematic human dissections were carried out by the Ancient Greek physicians Herophilus of Chalcedon and Erasistratus of Chios in the early part of the third century BC. The first physician known to have made postmortem dissections was the Arabian physician Avenzoar (1091–1161). Rudolf Virchow (1821–1902) is generally recognized to be the father of microscopic pathology. Most early pathologists were also practicing physicians or surgeons.
Starmer pledges to give all veterans, young care leavers and victims of domestic abuse a "guaranteed roof over their head". Senedd members vote to withdraw proposals to require parties to ensure 50% of their candidates are women. 25 September – Unions win a nonbinding vote at the Labour Party Conference calling on the government to reverse its cuts to winter fuel payments. Former Conservative MP and government minister Michael Gove is appointed as editor of The Spectator, and will take up the post in early October. Conservative Senedd member Natasha Asghar is reprimanded by Senedd authorities for calling Wales' 20 mph speed limit a "blanket" policy on social media, while signing off a report advising her party to refrain from using the term. 26 September – Starmer and Foreign Secretary David Lammy hold their first meeting with Donald Trump, attending a two-hour dinner with the Republican presidential candidate in New York. Former Conservative Party chairwoman Baroness Saeeda Warsi resigns from the party in the House of Lords, saying it has lurched to the "far-right". 27 September – 2024 Scottish Conservatives leadership election: Russell Findlay is elected as the new leader of the Scottish Conservatives, succeeding Douglas Ross. The Senedd Commission forecasts it will need an extra £1.2m in 2025–26 to prepare for a larger Senedd at the 2026 election. 28 September – Rosie Duffield, MP for Canterbury, resigns from the Labour Party, citing what she describes as it "cruel" policies and Keir Starmer's "staggering hypocrisy" over his acceptance of gifts.
The Brazilian Communist Party (Portuguese: Partido Comunista Brasileiro, PCB), originally the Communist Party of Brazil (Portuguese: Partido Comunista do Brasil), is a Marxist-Leninist party in Brazil, founded on 25 March 1922. Arguably the oldest active political party in Brazil, it played an important role in the country's 20th-century history despite the relatively small number of members. During the First Brazilian Republic era, the party opposed the ruling political order. Although the PCB was founded after the end of the tenentism movement, its most prominent leader, Luís Carlos Prestes, had previously led the Coluna Prestes (a rebel army which marched throughout the country) and later joined the party, becoming one of its leading figures. The PCB supported the Revolution of 1930 before later becoming an opponent of the Vargas government. The party was outlawed during the Estado Novo (1937–1945), briefly returned to legality after the dictatorship's fall, and was banned again in 1947, remaining underground for most of the following four decades. In the 1960s, the Sino-Soviet split led to a factional dispute that resulted in the formation of the PCdoB (Communist Party of Brazil) of Maoist orientation. Despite the split, both communist parties were united in opposition to the Brazilian military government that ruled from 1964 to 1985.
Californium is produced in nuclear reactors and particle accelerators. Californium-250 is made by bombarding berkelium-249 (249Bk) with neutrons, forming berkelium-250 (250Bk) via neutron capture (n,γ) which, in turn, quickly beta decays (β−) to californium-250 (250Cf) in the following reaction:
Sources: en.wikipedia.org
For the 1994–95 season, Barnsley turned to midfielder Danny Wilson to manage the club. His first season brought a sixth-place finish in the First Division, which would normally have meant a play-off place, but a restructuring of the league meant that they missed out. They finished 10th a year later before finally emerging as serious promotion contenders in the 1996–97 season, finally clinching runners-up spot and automatic promotion and gaining the top flight place that they had spent 99 years trying to win. Barnsley lasted just one season in the Premier League but they did reach the quarter-finals of the FA Cup, defeating Manchester United in the fifth round. They also made their record signing that season with Georgi Hristov for £2 million. Wilson then departed to take over at Sheffield Wednesday, being succeeded as Barnsley manager by striker John Hendrie, who had been a key player in the promotion-winning team. Barnsley were the only team from outside the Premier League to reach the quarter-finals of the FA Cup in the 1998–99 season, but only finished 13th in the league. Hendrie was then replaced as manager by Dave Bassett, who rejuvenated the team and took them to fourth place in 1999–2000. The team lost in the play-off final to Ipswich Town, the last play-off final at Wembley before the stadium was closed for redevelopment.
== Mechanisms of action == The mechanisms of action of artesunate remains unclear and debatable. Artesunate is a prodrug that is rapidly converted to its active form dihydroartemisinin (DHA). This process involves hydrolysis of the 4-carbon ester group via plasma esterase enzyme. It is hypothesized that the cleavage of endoperoxide bridge in the pharmacophore of DHA generates reactive oxygen species (ROS), which increases oxidative stress and causes malarial protein damage via alkylation. In addition, Artesunate potently inhibits the essential Plasmodium falciparum exported protein 1 (EXP1), a membrane glutathione S-transferase. As a result, the amount of glutathione in the parasite is reduced. In 2016, artemisinin has been shown to bind to a large number targets, suggesting that it acts in a promiscuous manner. There is evidence suggesting DHA inhibition of calcium-dependent ATPase on endoplasmic membrane, which disrupts protein folding of parasites. It has also been reported to target tubulin, favorizing its polymerization.
=== Migraine === Migraine occurs with episodes of intense headache causing nausea and throbbing pain. Stress and hormonal changes can be a trigger migraine. A nasal spray containing sumatriptan demonstrated a significant reduction of migraine pain. Further clinical studies of intranasal administration of sumatriptan (ST) can help evaluate efficacy and safety of such delivery systems. Since its approval by the FDA in 2021, dihydroergotamine mesylate has been administered through nasal sprays to treat migraines.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.